Lack of rapid virological response predicts interferon-α2b/ribavirin therapy failure in HCV genotype 2 patients: A single-centre study

Maria Grazia Rumi, Alessio Aghemo, Roberta D'Ambrosio, Guido Ronchi, Ersilio Del Ninno, Silvano Gallus, Massimo Colombo

Research output: Contribution to journalArticle

Abstract

Background: A minority of patients with HCV-2 chronic hepatitis does not attain a sustained virological response to interferon-based therapies. Registration trials have failed to identify the real proportion of HCV-2 non-responders, and predictors of non-response. The analysis of 'real-life' HCV-2 patients might help define the effectiveness of anti-HCV therapy and the role of response moderators. Methods: A re-analysis of all treatment-naive HCV-2 patients who consecutively received weight-dosed ribavirin with either 3 MU three times a week standard interferon-α2b or 1.5 μg/kg/week pegylated interferon-α2b. Results: The 94 interferon-treated patients and the 136 pegylated-interferon-treated patients were comparable for demography, prevalence of cirrhosis (25%) and adherence to therapy (74%). By intention-to-treat analysis, the overall sustained virological response rate was 80% (82% interferon versus 78% pegylated interferon). Overall, sustained virological rates were 83% for the 182 patients who cleared HCV RNA at week 4 (rapid virological response) and 52% for the 48 who did not (P

Original languageEnglish
Pages (from-to)1033-1040
Number of pages8
JournalAntiviral Therapy
Volume12
Issue number7
Publication statusPublished - 2007

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Lack of rapid virological response predicts interferon-α2b/ribavirin therapy failure in HCV genotype 2 patients: A single-centre study'. Together they form a unique fingerprint.

  • Cite this